September 13, 2019 10:27 AM EDT
News Briefing

Wood­ford forced to write down val­ues of hold­ings; No­var­tis show­cas­es pos­i­tive PhI­II MS da­ta

ENDPOINTS

→ Neil Wood­ford‘s in­vest­ment trust was forced to write down the val­ue of one its hold­ings to­day by just un­der $40 mil­lion, an­oth­er tum­ble …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

RFK Jr. ends an­nu­al Covid vac­cine rec­om­men­da­tions for kids, preg­nant women

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times